Ascendis Pharma stock
Price history
+33.39% over the period1 year: from $206.45 (November 13, 2025) to $275.39 (November 13, 2026), +33.39%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $275.39 |
| October 30, 2026 | $251.27 |
| September 30, 2026 | $227.83 |
| August 31, 2026 | $263.04 |
| July 31, 2026 | $243.91 |
| June 30, 2026 | $266.72 |
| May 29, 2026 | $224.11 |
| April 30, 2026 | $229.38 |
| March 31, 2026 | $228.73 |
| February 27, 2026 | $233.50 |
| January 30, 2026 | $226.10 |
| December 31, 2025 | $213.24 |
| November 28, 2025 | $212.33 |
| November 13, 2025 | $206.45 |
At a glance
The company
Biopharmaceutical company developing TransCon-based therapies for rare endocrine diseases and oncology indications
Latest results
Quarter to September 30, 2026 · EPS €1.71 (estimate €0.80)
TickerLandia's take on Ascendis Pharma
- Cheaper than similar companies: trailing 12-month P/E 18 vs 25 (−28%) in a group of 7.
- Strong point: Profitability (86/100 in its group). Weak point: Earnings stability (10/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.40% from the 52-week high
Analysts · 21 analysts
Average target$315.20+14.46% vs. price
Buy 20 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Ascendis Pharma
Compared with similar companies: very low earnings stability and very high profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage55
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 22.9 41 Price/book 10.7 75 Price/sales 15.0 62 P/E (trailing 12 months) 18.1 19 EV/EBITDA 46.5 78 Profitabilityvery high86
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 91.9% 76 Operating margin 30.9% 75 Net margin 72.9% 96 ROE 132.2% 96 ROA 13.0% 89 Earnings stabilityvery low10
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2,484.5% 9 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthhigh60
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +141.43% 90 Revenue growth (year over year) +73.00% 87 Earnings growth (year over year) −445.24% 3 Financial strengthlow35
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −1.69 29 Debt/equitycounts in reverse: lower means more financial strength 0.30 38 Current ratio 2.89 40 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong76
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +15.35% 85 1-year return +33.39% 76 Relative strength (6 months) +11.30% 65 Distance from 200-day average +14.82% 81 Risklow40
How much the price swings.
Metric Value Position in group Beta (1 year) 0.40 36 Volatility (60 days) 37.3% 58 Maximum drawdown (12 months) 19.7% 25
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Ascendis Pharma is cheaper than similar companies
Ascendis Pharma's P/E (trailing 12 months): 18.1, −28% against the median of a group of 7 similar companies (25.1).
Compared with 7 similar companies
| Metric | Ascendis Pharma | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 18.1 | Low | |
| Forward P/E | 22.9 | Middle | |
| Operating margin | 30.9% | Middle | |
| ROE | 132.2% | High | |
| Debt/equity | 0.30 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Ascendis Pharma. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€339.29M
Latest quarter · Q2 2026
Net income
€206.97M
Latest quarter · Q2 2026
Quarterly net margin
61.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $18.06B
- P/E
- 18.1
- EPS
- $15.21
- Volume
- 826.04K
- Daily trading
- €159.99M
- Dividend yield
- 0.00%
How Ascendis Pharma is changing
All resultsRevenue grew 153.0% a year on average over the last 5 years
Operating margin rose from −1,097.9% to −18.9%
Shares outstanding up 19.7% in 5 years
Returns
Ascendis Pharma returns
$1,000 invested in Ascendis Pharma 5 years ago, on November 15, 2021, would be worth $1,798 today: +79.83% in total, +12.47% per year. This is the price return only: dividends are excluded.
| Period | Ascendis Pharma | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +23.38% | −3.12% | $1,234 |
| 6 months | +13.06% | +1.58% | $1,131 |
| Year to date | +29.15% | +10.46% | $1,291 |
| 1 year | +33.39% | +12.23% | $1,334 |
| 3 years | +207.94% | +71.41% | $3,079 |
| 5 years | +79.83% | +61.48% | $1,798 |
| 10 years | +1,253.93% | +249.40% | $13,539 |
Over the last 6 months it has done better than 41% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Ascendis Pharma: technical analysis
Ascendis Pharma is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.6% below its all-time closing high ($277.18, July 8, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 75
- Above 70: a strong rise in a short time
- vs 200-session average
- +14.82%
Active signals
Close above the high of the previous 55 sessions.
RSI above 70: the stock has risen a lot in a short time.
since November 12, 2026
Support and resistance
Price areas where Ascendis Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$275.39
- Support$260.91−5.26%2 touches, last on August 19, 2026
- Support$249.17−9.52%5 touches, last on August 28, 2026
- Support$240.00−12.85%4 touches, last on August 14, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.40
- Volatility (60 sessions, annualised)
- 37.3%
- Largest fall in the last year
- −19.66%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Ascendis Pharma: seasonality
Average monthly price change over 12 years
Over the last 12 years, the strongest month for Ascendis Pharma has been August: +8.44% on average, positive in 9 years out of 12. The weakest has been April: −3.10% on average, positive in 5 years out of 12. November, the current month, has been positive in 9 years out of 11 (+4.74% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.13% | +3.16% | 7 of 11 |
| February | +5.07% | +2.56% | 7 of 12 |
| March | +3.04% | −1.25% | 5 of 12 |
| April | −3.10% | −2.75% | 5 of 12 |
| May | −0.51% | −2.36% | 4 of 12 |
| June | +3.50% | +2.14% | 8 of 12 |
| July | −0.68% | +0.53% | 7 of 12 |
| August | +8.44% | +6.20% | 9 of 12 |
| September | +2.53% | +2.02% | 7 of 12 |
| October | −0.04% | −0.87% | 6 of 12 |
| November | +4.74% | +5.32% | 9 of 11 |
| December | +4.20% | +0.43% | 6 of 11 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Ascendis Pharma and its competitors
Founded in 2006, Ascendis Pharma A/S is based in Hellerup, Denmark, and develops therapies built on its TransCon technology for rare conditions with unmet medical needs in Europe, the United States and other markets. Its marketed products include SKYTROFA, prescribed to children with growth hormone shortfall, and YORVIPATH, a daily subcutaneous injection for adults with chronic hypoparathyroidism. The company also has three endocrinology rare disease candidates in clinical development and advances oncology candidates.
- Headquarters
- Hellerup, Denmark
- Employees
- 1,189
- Founded
- 2006
- Chief executive
- Jan Mikkelsen
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Ascendis PharmaASND | $18.06B | 30.9% | 18.1 | +13.06% |
| ExelixisEXEL | $16.84B | 40.2% | 20.7 | +34.53% |
| Jazz PharmaceuticalsJAZZ | $15.5B | 27.4% | 71.5 | +3.97% |
| BioNTechBNTX | $21.22B | -55.4% | — | −7.19% |
| BridgeBio PharmaBBIO | $15.25B | -37.3% | — | +14.12% |
| Alnylam PharmaceuticalsALNY | $22.11B | 19.5% | 8.34 | −43.38% |
Same industry or related industries, similar size. Compare Ascendis Pharma with its competitors · Full profile
